FDA Accepts Remicade Psoriatic Arthritis Submission, J&J Says
FDA has accepted a supplemental BLA for Johnson & Johnson's Remicade for the treatment of psoriatic arthritis in patients with active disease, the company said Dec. 1
FDA has accepted a supplemental BLA for Johnson & Johnson's Remicade for the treatment of psoriatic arthritis in patients with active disease, the company said Dec. 1